ARPO Aerpio Pharmaceuticals Inc

DGAP-News: MackeyRMS Announces APAC Expansion

DGAP-News: MackeyRMS / Key word(s): Miscellaneous
MackeyRMS Announces APAC Expansion

06.03.2019 / 02:00
The issuer is solely responsible for the content of this announcement.


Leading RMS provider names industry veteran Nathan Walker to newly created post

BOSTON, MA / ACCESSWIRE / March 5, 2019 / , the leading provider of next-generation research management software, announced the appointment of industry veteran to a newly created position overseeing Asia-Pacific (APAC) business development to build on the company's strategic plan for global expansion.

Mr. Walker joins Mackey from Thomson Reuters, where he worked with asset owners and managers on research unbundling and building-out research capabilities as Head of Market Development, Investment & Advisory, Pacific. He previously oversaw the expansion of a leading electronic trading provider, TradingScreen, to Singapore and Sydney. Walker also spent a number of years working with traditional asset managers, sovereign wealth funds and hedge funds on front-office trading and research solutions as a Bloomberg Sales Team Leader in Singapore and Sydney.

''We are thrilled to have Nathan Walker represent our team in Asia Pacific. His deep understanding of the workflow relationship between research and trading across APAC-based institutions is unrivaled, and I look forward to working alongside him as we expand our footprint in the region,'' said Chris Mackey, Founder and CEO of MackeyRMS.

With over 25 years' experience in investment management technology, Walker is well-suited to build upon Mackey's early success in the APAC region. ''I am extremely pleased to join Mackey at this time and help expand their business across the Asia-Pacific. Asset owners and managers here have been focusing on streamlining their research workflow to become more productive,'' said Walker.

Walker comes to Mackey following a year that saw the company double investment management clients' assets under management to over $2 trillion. Mackey's global client roster boasts asset managers, fund of funds and hedge funds, while its end-users reside in over 30 countries.

About MackeyRMS

MackeyRMSâ„¢ is leading SaaS-based research management software optimized for investment professionals. Highly automated and ultra-portable, MackeyRMS works with users' existing devices and applications to seamlessly aggregate and organize both external and proprietary research content. For more information, please visit:

Contacts:

Media

Lauren Herman
Caliber Corporate Advisers

Sales

Nathan Walker
Institutional Sales Manager - APAC, MackeyRMS

SOURCE: MackeyRMS



06.03.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


Language: English
Company: MackeyRMS
United States

 
End of News DGAP News Service

784303  06.03.2019 

fncls.ssp?fn=show_t_gif&application_id=784303&application_name=news&site_id=research_pool
EN
06/03/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aerpio Pharmaceuticals Inc

 PRESS RELEASE

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes LOS ANGELES, June 23, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced it will join both the U.S. small cap Russell 2000® Index and broad-market Russell 3000® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective immediately after the U.S. market opens on June 24, 2022 according to a preliminary list of add...

 PRESS RELEASE

Aadi Bioscience to Present at the Jefferies Global Healthcare Conferen...

Aadi Bioscience to Present at the Jefferies Global Healthcare Conference LOS ANGELES, June 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced members of the Aadi senior management team will participate in the Jefferies Global Healthcare Conference, to be held in New York, NY June 8-10, 2022. Founder, Chief Executive Officer and President, Neil Desai, Ph.D. is scheduled to present live during a fire...

 PRESS RELEASE

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor R...

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced the appointment of Marcy Graham to the new position of Senior Vice President, Investor Relations (IR) and Corporate Communications. “We are delighted to welcome Marcy to the team, as she brings extensive experience to ...

 PRESS RELEASE

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in ...

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations regardless of prior mTOR inhibitor exposure LOS ANGELES, May 26, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced presentat...

 PRESS RELEASE

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Co...

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., and senior members of Aadi’s executive team will participate virtually in the H.C. Wainwright Global Investment Conference, to be held in person and virtually May 23-26, 2022 in Mia...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch